Use of a genetically attenuated strain of Aeromonas salmonicida to vaccinate salmonid fish

M. J. Marsden, A. Devoy, L. M. Vaughan, T. J. Foster, C. J. Secombes*

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A genetically attenuated strain of Aeromonas salmonicida has been developed that has a complete deletion of the aroA gene (Brivax II), making it suitable for development as a commercial vaccine. Brivax II was effectively cleared from Atlantic salmon, Salmo salar, a species highly susceptible to furunculosis, confirming that it is attenuated. Clearance rate was dependent on the vaccine dose administered, being longer with higher doses. Immunological studies using Brivax II injected in rainbow trout, Oncorhynchus mykiss, confirmed that live vaccines stimulate a greater response, in terms of generating leucocytes able to proliferate to a subsequent encounter with antigen, relative to killed vaccines. Development of strains of Brivax II as carriers of heterologous antigens was also investigated. Escherichia coli β-galactosidase was chosen as the model antigen, and three strains containing plasmids with the LacZ gene were constructed (Brivax 12, Brivax 61 and Brivax 107). All three strains were shown to express β-galactosidase in vivo in rainbow trout and to be cleared effectively. Interestingly, Brivax 107 was cleared faster than the other two Lac+ strains and had the highest level of β-galactosidase activity. The two strains expressing lower levels of activity also behaved differently in vivo, in that Brivax 12 accumulated derivatives expressing lower levels of β-galactosidase activity, suggesting that mutants are being selected in vivo. The potential advantages of live vaccines over killed vaccines are discussed.

Original languageEnglish
Pages (from-to)55-66
Number of pages12
JournalAquaculture International
Volume4
Issue number1
DOIs
Publication statusPublished - Mar 1996

Fingerprint

Aeromonas salmonicida
vaccine
salmonid
galactosidases
fish
antigen
Oncorhynchus mykiss
inactivated vaccines
live vaccines
antigens
Salmo salar
rainbow
vaccines
furunculosis
clearance rate
gene
administered dose
plasmid
leukocytes
plasmids

Keywords

  • Aeromonas salmonicida
  • aroA
  • Furunculosis
  • Genetically attenuated live vaccine
  • Immune response
  • Salmonids
  • β-galactosidase

ASJC Scopus subject areas

  • Aquatic Science
  • Agronomy and Crop Science

Cite this

Use of a genetically attenuated strain of Aeromonas salmonicida to vaccinate salmonid fish. / Marsden, M. J.; Devoy, A.; Vaughan, L. M.; Foster, T. J.; Secombes, C. J.

In: Aquaculture International, Vol. 4, No. 1, 03.1996, p. 55-66.

Research output: Contribution to journalArticle

Marsden, M. J. ; Devoy, A. ; Vaughan, L. M. ; Foster, T. J. ; Secombes, C. J. / Use of a genetically attenuated strain of Aeromonas salmonicida to vaccinate salmonid fish. In: Aquaculture International. 1996 ; Vol. 4, No. 1. pp. 55-66.
@article{032ba653e8714859bb0e0434e4d09acb,
title = "Use of a genetically attenuated strain of Aeromonas salmonicida to vaccinate salmonid fish",
abstract = "A genetically attenuated strain of Aeromonas salmonicida has been developed that has a complete deletion of the aroA gene (Brivax II), making it suitable for development as a commercial vaccine. Brivax II was effectively cleared from Atlantic salmon, Salmo salar, a species highly susceptible to furunculosis, confirming that it is attenuated. Clearance rate was dependent on the vaccine dose administered, being longer with higher doses. Immunological studies using Brivax II injected in rainbow trout, Oncorhynchus mykiss, confirmed that live vaccines stimulate a greater response, in terms of generating leucocytes able to proliferate to a subsequent encounter with antigen, relative to killed vaccines. Development of strains of Brivax II as carriers of heterologous antigens was also investigated. Escherichia coli β-galactosidase was chosen as the model antigen, and three strains containing plasmids with the LacZ gene were constructed (Brivax 12, Brivax 61 and Brivax 107). All three strains were shown to express β-galactosidase in vivo in rainbow trout and to be cleared effectively. Interestingly, Brivax 107 was cleared faster than the other two Lac+ strains and had the highest level of β-galactosidase activity. The two strains expressing lower levels of activity also behaved differently in vivo, in that Brivax 12 accumulated derivatives expressing lower levels of β-galactosidase activity, suggesting that mutants are being selected in vivo. The potential advantages of live vaccines over killed vaccines are discussed.",
keywords = "Aeromonas salmonicida, aroA, Furunculosis, Genetically attenuated live vaccine, Immune response, Salmonids, β-galactosidase",
author = "Marsden, {M. J.} and A. Devoy and Vaughan, {L. M.} and Foster, {T. J.} and Secombes, {C. J.}",
year = "1996",
month = "3",
doi = "10.1007/BF00175221",
language = "English",
volume = "4",
pages = "55--66",
journal = "Aquaculture International",
issn = "0967-6120",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Use of a genetically attenuated strain of Aeromonas salmonicida to vaccinate salmonid fish

AU - Marsden, M. J.

AU - Devoy, A.

AU - Vaughan, L. M.

AU - Foster, T. J.

AU - Secombes, C. J.

PY - 1996/3

Y1 - 1996/3

N2 - A genetically attenuated strain of Aeromonas salmonicida has been developed that has a complete deletion of the aroA gene (Brivax II), making it suitable for development as a commercial vaccine. Brivax II was effectively cleared from Atlantic salmon, Salmo salar, a species highly susceptible to furunculosis, confirming that it is attenuated. Clearance rate was dependent on the vaccine dose administered, being longer with higher doses. Immunological studies using Brivax II injected in rainbow trout, Oncorhynchus mykiss, confirmed that live vaccines stimulate a greater response, in terms of generating leucocytes able to proliferate to a subsequent encounter with antigen, relative to killed vaccines. Development of strains of Brivax II as carriers of heterologous antigens was also investigated. Escherichia coli β-galactosidase was chosen as the model antigen, and three strains containing plasmids with the LacZ gene were constructed (Brivax 12, Brivax 61 and Brivax 107). All three strains were shown to express β-galactosidase in vivo in rainbow trout and to be cleared effectively. Interestingly, Brivax 107 was cleared faster than the other two Lac+ strains and had the highest level of β-galactosidase activity. The two strains expressing lower levels of activity also behaved differently in vivo, in that Brivax 12 accumulated derivatives expressing lower levels of β-galactosidase activity, suggesting that mutants are being selected in vivo. The potential advantages of live vaccines over killed vaccines are discussed.

AB - A genetically attenuated strain of Aeromonas salmonicida has been developed that has a complete deletion of the aroA gene (Brivax II), making it suitable for development as a commercial vaccine. Brivax II was effectively cleared from Atlantic salmon, Salmo salar, a species highly susceptible to furunculosis, confirming that it is attenuated. Clearance rate was dependent on the vaccine dose administered, being longer with higher doses. Immunological studies using Brivax II injected in rainbow trout, Oncorhynchus mykiss, confirmed that live vaccines stimulate a greater response, in terms of generating leucocytes able to proliferate to a subsequent encounter with antigen, relative to killed vaccines. Development of strains of Brivax II as carriers of heterologous antigens was also investigated. Escherichia coli β-galactosidase was chosen as the model antigen, and three strains containing plasmids with the LacZ gene were constructed (Brivax 12, Brivax 61 and Brivax 107). All three strains were shown to express β-galactosidase in vivo in rainbow trout and to be cleared effectively. Interestingly, Brivax 107 was cleared faster than the other two Lac+ strains and had the highest level of β-galactosidase activity. The two strains expressing lower levels of activity also behaved differently in vivo, in that Brivax 12 accumulated derivatives expressing lower levels of β-galactosidase activity, suggesting that mutants are being selected in vivo. The potential advantages of live vaccines over killed vaccines are discussed.

KW - Aeromonas salmonicida

KW - aroA

KW - Furunculosis

KW - Genetically attenuated live vaccine

KW - Immune response

KW - Salmonids

KW - β-galactosidase

UR - http://www.scopus.com/inward/record.url?scp=0030067189&partnerID=8YFLogxK

U2 - 10.1007/BF00175221

DO - 10.1007/BF00175221

M3 - Article

VL - 4

SP - 55

EP - 66

JO - Aquaculture International

JF - Aquaculture International

SN - 0967-6120

IS - 1

ER -